AEF vs VYGR Comparison

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a non-diversified closed-end, management investment company. Its investment objective is to seek to provide both current income and long-term capital appreciation. Under normal circumstances, the fund invests a majority of its net assets (plus any borrowings for investment purposes) in emerging markets (excluding China) equity securities. The performance of the fund is measured against the MSCI Emerging Markets ex-China Index. Its investment portfolio consists of equity securities from emerging market companies (excluding China), spanning multiple sectors such as Information Technology, Financials, Industrials, Consumer Discretionary, Real Estate, and others.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.